Monday, November 30, 2009

Two-for-One Special over at Health Care Renewal

Roy Poses over at the Health Care Renewal site has been blogging up a storm. Rather than try to summarize or encapsulate, I'll simply point toward two valuable posts:

On yet more evidence of systematic suppression of negative study data regarding antidepressants:

On the question of why Genzyme can charge $160,000 a year for its drug to treat Gaucher's disease, and pay its CEO $50M a year, but cannot manage to get its factory to turn out non-contaminated supplies of the drug:

No comments: